ATON

AlphaTON Capital Corp

Oct 17 • 04:00PM ET

5.82

-0.54 -8.49 %

Financial • Asset Management • United Kingdom • NASD

Peers: VRTX GILD AMGN REGN ROG BMRN BIIB BNTX EXEL INCY

Index	-	P/E	-	EPS (ttm)	-65.69	Insider Own	62.92%	Shs Outstand	5.88M	Perf Week	-7.62%
Market Cap	34.23M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.18M	Perf Month	-7.32%
Enterprise Value	31.80M	PEG	-	EPS next Q	-	Inst Own	0.35%	Short Float	0.91%	Perf Quarter	0.17%
Income	-67.28M	P/S	-	EPS this Y	-	Inst Trans	-1.84%	Short Ratio	0.02	Perf Half Y	-25.77%
Sales	0.00M	P/B	4.65	EPS next Y	-	ROA	-136.43%	Short Interest	0.02M	Perf YTD	12.57%
Book/sh	1.25	P/C	19.45	EPS next 5Y	-	ROE	-194.84%	52W High	15.82 -63.21%	Perf Year	-7.03%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	39.50% 10.10%	ROIC	-4812.45%	52W Low	2.95 97.29%	Perf 3Y	-95.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.09% 13.05%	Perf 5Y	-97.06%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	48.91%	Oper. Margin	-	ATR (14)	1.25	Perf 10Y	-97.20%
Dividend Ex-Date	-	Quick Ratio	3.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.32	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.08	EPS Q/Q	78.19%	SMA20	-9.16%	Beta	0.56	Target Price	140.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-15.47%	Rel Volume	0.15	Prev Close	6.36
Employees	-	LT Debt/Eq	0.00	Earnings	Jul 25 AMC	SMA200	-8.21%	Avg Volume	791.23K	Price	5.82
IPO	Jan 21, 1999	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	114,792	Change	-8.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$26
Mar-07-22	Initiated	H.C. Wainwright	Buy	$32
Sep-21-21	Initiated	Oppenheimer	Outperform	$30
Sep-02-21	Initiated	B. Riley Securities	Buy	$40
Aug-19-21	Initiated	Cantor Fitzgerald	Overweight	$35

Oct-15-25 08:16AM	AlphaTON Capital Powers TOKEN2049 "Origins" Hackathon in Singapore (GlobeNewswire) -8.56%
Oct-14-25 07:00AM	AlphaTON Capital CEO Brittany Kaiser and SkyBridge Capital Founder Anthony Scaramucci Join Schwab Network's Trading 360 to Discuss Crypto Innovation and Cancer Research Funding (GlobeNewswire) +9.02%
Oct-13-25 07:26AM	AlphaTON Capital Launches AI Vertical with MorpheusAI to Accelerate Agentic AI Development on TON and Telegram (GlobeNewswire)
Oct-12-25 09:00PM	Market Alert: AlphaTON Capital Continues in Growth Mode and Purchases an additional 300,000 TON (GlobeNewswire)
Oct-11-25 09:48AM	Health In Tech, AlphaTON Partner to Develop 'HITChain' Blockchain Platform for Healthcare Claims on TON (Insider Monkey)
08:02AM	Loading…
Oct-10-25 08:02AM	AlphaTON Capital Receives Nasdaq Congratulations for Groundbreaking Cancer Research Tokenization Initiative (GlobeNewswire) -24.55%
Oct-09-25 08:53AM	AlphaTON Capital CIO and Executive Chairman Enzo Villani Featured in Live Interview at Nasdaq MarketSite with IPO Edge (GlobeNewswire) -23.46%
Oct-08-25 07:16AM	AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing (GlobeNewswire) +95.52%
Oct-07-25 09:39AM	TON on Telegram Ecosystem: AlphaTON Capital CIO Enzo Villani, Live at Nasdaq (Exec Edge)
Sep-25-25 02:45PM	AlphaTON Capital Corp Successfully Closes $71 million Financing and Completes Initial TON Token Acquisition (GlobeNewswire)
Sep-03-25 12:37PM	AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem (GlobeNewswire)
Jul-25-25 04:15PM	Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 (GlobeNewswire)
Jun-25-25 07:00AM	Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) +13.57%
Jun-09-25 06:00AM	Portage Biotech and Compedica Stock-for-Stock Exchange (GlobeNewswire) -9.63%
Apr-28-25 06:00AM	Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 (GlobeNewswire) +27.46%
04:15PM	Loading…
Mar-27-25 04:15PM	Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 (GlobeNewswire) +103.82%
Mar-12-25 08:00AM	Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial (GlobeNewswire)
Feb-12-25 04:15PM	Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements (GlobeNewswire)
Jan-30-25 04:30PM	Portage Biotech Announces Completion of $2.15 Million Private Financing (GlobeNewswire)
Jan-06-25 05:00AM	Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company (GlobeNewswire)
Dec-17-24 07:00AM	Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd (GlobeNewswire) +178.15%
Dec-12-24 04:15PM	Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter (GlobeNewswire) -21.47%
Nov-26-24 04:05PM	Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 (GlobeNewswire) -13.55%
Aug-27-24 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update (GlobeNewswire)
Aug-15-24 07:00AM	Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update (GlobeNewswire) +62.79%
Aug-13-24 07:00AM	Portage Biotech Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -18.10%
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Apr-15-24 07:05AM	Immuno-oncology company Portage Biotech to evaluate strategic alternatives (Pharmaceutical Business Review) -25.27%
Apr-12-24 10:33AM	Portage Biotech previews possible closure as it halts programs, hunts for strategic options (FierceBiotech.com) -9.00%
08:01AM	Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives (GlobeNewswire)
08:01AM	Loading…
Mar-26-24 08:01AM	Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares (GlobeNewswire) +9.73%
Feb-28-24 05:10PM	Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update (GlobeNewswire) -15.71%
Jan-04-24 08:00AM	Portage Biotech Reports Business and Strategic Update (GlobeNewswire)
Nov-28-23 04:01PM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update (GlobeNewswire) +8.46%
Nov-06-23 08:01AM	Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-29-23 08:00AM	Portage Biotech Announces $6.0 Million Registered Direct Offering (GlobeNewswire) -7.52%
Sep-20-23 08:00AM	Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors (GlobeNewswire) +26.81%
Aug-30-23 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update (GlobeNewswire) -13.36%
Jul-31-23 04:05PM	Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire) +7.69% -7.76%
Jun-26-23 08:00AM	Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors (GlobeNewswire)
Jun-05-23 08:00AM	Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-01-23 08:00AM	Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference (GlobeNewswire) +5.17%
Apr-26-23 05:00PM	Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Portage Biotech to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.69%
Mar-01-23 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022 (GlobeNewswire)
Feb-27-23 04:05PM	Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer (GlobeNewswire) +6.94%
Feb-15-23 08:00AM	Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Nov-29-22 04:43PM	Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022 (GlobeNewswire)
Nov-10-22 09:00AM	Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Nov-08-22 08:00AM	Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck (GlobeNewswire)
Sep-14-22 08:39AM	Portage Biotech Provides Research and Development Update (GlobeNewswire)
Sep-08-22 08:00AM	Portage Biotech to Present at Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-29-22 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022 (GlobeNewswire)
Aug-18-22 08:00AM	Portage Biotech Announces Leadership Updates (GlobeNewswire)
Aug-01-22 09:10AM	UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
Jul-20-22 09:00AM	Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform (GlobeNewswire) +6.13%
Jul-06-22 04:05PM	Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway (GlobeNewswire)
Jun-06-22 08:00AM	Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study (GlobeNewswire) -8.47%
Apr-25-22 08:00AM	Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity (GlobeNewswire) +8.33%
Apr-13-22 10:00AM	Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting (GlobeNewswire) +8.95%
Mar-31-22 08:00AM	Portage Biotech Provides Update on Clinical-Stage and Development Programs (GlobeNewswire)
Mar-09-22 09:00AM	Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-24-22 05:43PM	Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year (GlobeNewswire) +13.79%
Feb-15-22 08:00AM	Portage Biotech Announces New Appointments to its Management Team and Board of Directors (GlobeNewswire) +11.90%
Jan-05-22 08:00AM	Portage Biotech Announces Participation in January 2022 Investor Conferences (GlobeNewswire)
Nov-23-21 08:00AM	Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year (GlobeNewswire)
Nov-22-21 04:53PM	Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire) -7.06%
Nov-15-21 08:00AM	Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics INT230-6 (PORT-1) at November Scientific Conferences (GlobeNewswire)
Nov-10-21 08:00AM	Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment (GlobeNewswire) -6.53%
Oct-26-21 10:13AM	2 Strong Buy Stocks Oppenheimer Predicts Will Surge at Least 50% (TipRanks)
Sep-10-21 08:00AM	Portage Biotech Announces Participation in September 2021 Investor Conferences (GlobeNewswire)
Aug-30-21 08:00AM	Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year (GlobeNewswire)
Aug-12-21 08:00AM	Portage Biotech Issues Letter to Shareholders (GlobeNewswire)
Aug-05-21 08:00AM	Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire) +14.29%
Jul-28-21 08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021 (GlobeNewswire)
Jun-29-21 09:00AM	Portage Biotech Added to Russell 2000(R) Index (Newsfile) -5.21%
Jun-24-21 09:00AM	Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares (Newsfile) -25.43%
08:56AM	Thursdays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks)
Jun-23-21 04:10PM	Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares (Newsfile)
Jun-02-21 08:30AM	Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting (Newsfile)
Apr-16-21 09:00AM	Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange (Newsfile) -7.06%
Apr-08-21 09:00AM	Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors (Newsfile)
Mar-25-21 09:00AM	Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics (Newsfile)
Mar-04-21 08:00AM	Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd (Newsfile) -17.86%
Mar-02-21 08:00AM	Portage Announces Filing of Third Quarter Financial Statements (Newsfile) +5.98%

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATON

AlphaTON Capital Corp

Upgrade your FINVIZ experience